Business
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON’s President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. Please register here to
About this update from Aeon Biopharma, Inc.
[{"type":"image","alt":"AEON Biopharma","displaySize":"","headline":null,"caption":"AEON Biopharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/4e5536b202731f8582e6bfa42a1b19a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dGy5RFZ4cSVxL8LejqiO2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4e5536b202731f8582e6bfa42a1b19a5","width":300,"height":73}},"lazy":false},{"type":"text","content":"IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that Rob Bancroft, AEON’s President and Chief Executive Officer, will present a corporate overview at the Aegis Capital Corp. 2025 Virtual Conference on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET.","length":475,"tagName":"p"},{"type":"text","content":"Please register here to attend the conference on Wednesday, May 21st.","length":69,"tagName":"p"},{"type":"text","content":"About AEON Biopharma","length":20,"tagName":"p"},{"type":"text","content":"AEON is a clinical stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection, or ABP-450, for debilitating medical conditions. ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus under the name Jeuveau. ABP-450 is manufactured by Daewoong in compliance with current Good Manufacturing Practice, or cGMP, in a facility that has been approved by the U.S. Food and Drug Administration, Health Canada and European Medicines Agency. The product is approved as a biosimilar in Mexico and India. AEON has exclusive development and distribution rights for therapeutic indications of ABP-450 in the United States, Canada, the European Union, the United Kingdom, and certain other international territories. The Company has built a highly experienced management team with specific experience in biopharmaceutical and botulinum toxin development and commercialization. To learn more about AEON, visit www.aeonbiopharma.com.","length":1055,"tagName":"p"},{"type":"text","content":"Contacts I...